iifl-logo

Bacil Pharma Ltd Board Meeting

40.57
(-2.00%)
May 5, 2025|12:00:00 AM

Bacil Pharma CORPORATE ACTIONS

10/05/2024calendar-icon
10/05/2025calendar-icon
PurposeBoard Meetings DateAnnouncement Date
Board Meeting21 Jan 202513 Jan 2025
BACIL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/01/2025 inter alia to consider and approve 1) the Un-Audited Financial Results along with Limited Review Report of the Company for the Quarter ended 31st December 2024. 2) Other routine business with the permission of the Chair. Outcome of Board meeting (As Per BSE Announcement Dated on: 21/01/2025)
Board Meeting12 Nov 202412 Nov 2024
Submission of Corrigendum to the Notice of EOGM dated 15/10/2024 submitted on 23/10/2024 as per attachment
Board Meeting23 Oct 202416 Oct 2024
BACIL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2024 inter alia to consider and approve 1) To consider and approve the Un-Audited Financial Results along with Statements of Assets and Liabilities and Cash Flow Statement of the Company for the Quarter and half year ended 30th September 2024. 2) Other routine business with the permission of the Chair. outcome of Board Meeting held on 23rd October 2024 (As Per BSE Announcement Dated on: 23/10/2024)
Board Meeting15 Oct 202410 Oct 2024
BACIL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/10/2024 inter alia to consider and approve items mentioned in the notice of Board meeting. Outcome of Board Meeting held on 15th October,2024 Approved the acquisition of 5527000 Equity shares of M/s. CNX Corporation Limited (CCL) subject to approval of members of the Company at ensuing Extra Ordinary General Meeting. Revised Outcome of Board Meeting due to clerical mistake in list of allotee. (As Per BSE Announcement dated on 15.10.2024)
Board Meeting27 Sep 202421 Sep 2024
BACIL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/09/2024 inter alia to consider and approve matters stated in intimation OUTCOME OF BOARD MEETING HELD ON 27TH SEPTEMBER, 2024. (As per BSE Announcement Dated on 27/09/2024)
Board Meeting2 Sep 20242 Sep 2024
Approval Of Notice Of Annual General Meeting And Board Of Directors Report, Fixation Of Book Closure For AGM And Remote Evoting Facility, Appointment Of Scrutinizer Along With Routine Business.
Board Meeting31 Aug 202431 Aug 2024
outcome of Board Meeting held on 31.08.2024
Board Meeting28 Aug 202428 Aug 2024
1. Considered & Approved Appointment of Ms. Avani Savjibhai Godhaniya (DIN: 10387729) as an Additional Director in the category of Non-Executive - Independent Director in the Company, not liable to retire by rotation, on the Board of Directors of the Company with effect from 28th August, 2024 for a first term of 5 (five) Years, i.e upto 27th August,2029 subject to members approval at its General Meeting. 2. Considered & Approved Appointment of Mr. Dinesh Chander Notiyal (DIN: 10289995) as an Additional Director in the category of Non-Executive - Independent Director in the Company , not liable to retire by rotation, on the Board of Directors of the Company with effect from 28th August,2024 for a first term of 5 (five) Years, i.e upto 27th August,2029 subject to members approval at its General Meeting.
Board Meeting14 Aug 20247 Aug 2024
BACIL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2024 inter alia to consider and approve 1. the Un-Audited Financial Results along with Limited Review Report for the Quarter ended 30th June 2024. 2. Any other item with permission of the Chair. Outcome of Board Meeting held on 14th August 2024 (As Per Bse Announcement Dated on 14.08.2024)
Board Meeting21 May 202414 May 2024
BACIL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2024 inter alia to consider and approve 1. the Audited Financial Results along with Auditors Report and Statement of Asset and Liabilities and Cash Flow Statement for the Quarter and Year ended 31st March 2024. 2. Any other item with permission of the Chair. Outcome of Board Meeting held on 21 May 2024 Financial Results along with Auditors Report & Statement of Assets & Liabilities & Cash Flow statement for the quarter and year ended 31st March 2024 Intimation for appointment of Secretarial Auditor of the company. Intimation for appointment of Internal Auditor of the Company (As Per BSE Announcement Dated on 21/05/2024)

Bacil Pharma: Related News

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.